BioPharma Credit - The silent yield specialist in the life science sector
Scores at time of recommendation (January 24, 2026)
5-year stock timeline
2026 Sep (post‑period investor materials / dividend updates)
Investor materials including a 24 September 2026 half‑year presentation and routine communications were released. The company continued publishing quarterly dividend declarations throughout 2026. Messaging reinforced BPCR's positioning as a specialist life‑sciences debt investor with a steady dividend orientation, emphasising continued income generation from a diversified loan portfolio [27][13].
2026 Jun–Jul (quarterly dividend declarations)
BPCR declared and paid quarterly dividends in mid‑2026, including a 1.75 US cent ordinary quarterly dividend announced in June and paid in July. Market perception held that BPCR targets a base annual ordinary dividend of 7 US cents, supplemented by special dividends when net income allows. Dividends remained the primary driver of shareholder returns. The company referenced 2025 total dividends of 9.95 US cents per share when describing recent dividend history, alongside prior years of 10.18 US cents (2024) and 10.21 US cents (2023) [13][3].
2025 Sep–Oct (interim dividend increase; half‑year report)
An increased interim dividend of 3.25 US cents per share was declared for the quarter ending 30 September 2025, payable 31 October 2025. The half‑year report and regulatory announcements detailed distributions for 2025 to date. The raised interim signalled stronger quarterly income recognition and management's willingness to increase short‑term distributions when underlying net income supported it. Dividends for calendar year 2025 to date were 6.75 US cents after the interim announcement; the company referenced the 2024 dividend of 10.18 US cents when comparing years [9][7].
2025 Mar (annual results for year ended 31 Dec 2024)
Audited Final Results for the year ended 31 December 2024 were published. Management reported net income per share of 9.99 US cents and declared a further Q4 2024 dividend comprising ordinary and special elements (2.892309 US cents, comprising 1.75 ordinary and 1.142309 special), payable 28 February 2025. Results emphasised resilience of BPCR's life‑science loans and recurring income. Management highlighted a track record of paying a quarterly ordinary dividend and using special dividends when net income exceeded the base target. NAV per share at 31 December 2024 was reported as $0.9963; total net assets were $1,181.7m as against $1,340.9m at 31 December 2023. The company paid 10.18 US cents in dividends for 2024 [17][10][6].
2024 (full year / dividend and net income commentary)
Annual reporting and investor updates for the 2024 financial year were published in early‑to‑mid 2025, summarising 2024 performance and distributions. The company reiterated its policy of a 7 US cent base annual ordinary dividend while using special dividends to distribute excess net income. Total dividends declared and paid in 2024 were 10.18 US cents per share, with net income per share for 2024 approximately 9.99 US cents [6][17].
2023 Mar–Apr (final results for year ended 31 Dec 2023)
Final Results for the year ended 31 December 2023 were published. The company reported NAV growth and investment activity including new investments and unfunded commitments. NAV per share increased 1.54 US cents to $1.0293 at 31 December 2023; total net assets were $1,340.9m. The reported share price at 31 December 2023 was $0.84 [16][23][28].
2023 H1 (30 June 2023 half‑year)
The half‑year report to 30 June 2023 disclosed portfolio composition, cash levels, and a modest NAV increase. The company reported investments made during 2023 and remaining unfunded commitments. NAV per share at 30 June 2023 was $1.0178 (up from $1.0139 at 31 December 2022); total net assets were approximately $1,328m. Investments were approximately $1,178m and cash approximately $154m as at 30 June 2023 [19][21].
2022 (annual reporting / steady distribution policy)
Annual report and ongoing quarterly dividend payments for 2022 were reported; the company maintained its ordinary dividend and paid special distributions in certain periods. Dividends for 2022 totalled approximately 13.08 US cents per share, and the company referenced maintaining at least 1.75 US cents per quarter ordinary dividends historically [5][12].
2021 (early post‑listing maturity and dividend track record)
BPCR continued executing its strategy of providing debt to life sciences companies and maintaining regular quarterly distributions. The recurring 1.75 US cent ordinary quarterly dividend was in place through and after 2021 [28][16].
Key Points
- Specialized lender for biotech and pharmaceutical companies with secured loans
- Dividend yield of 7.78% with share price close to 52-week low (USD 0.79-0.96)
- Impressive margins: 86.9% operating margin, 79.6% profit margin
- Equity ratio above 98% signals solid balance sheet structure
- Next dividend (USD 0.02) with ex-day 2. February 2026
Investment Thesis
BioPharma Credit occupies a niche in the life science sector that is often overlooked: The company grants collateralized loans to established biotech and pharmaceutical companies and benefits from the structural growth of the sector. Demographic change and rising healthcare expenditure ensure a continuous need for financing, while the business model focuses on companies with products that have already been approved or are about to be approved - which significantly reduces the risk profile compared to pure biotech bets. The combination of an attractive dividend yield, robust margins and defensive positioning makes BioPharma Credit an interesting option for income-oriented investors.
Key risks and downside factors
BioPharma Credit PLC (BPCR.LSE) is a UK-listed closed-ended investment trust that lends to life-sciences companies and acquires their income streams through royalties, structured loans, and secured debt. Its peers are specialist credit funds and alternative asset investment trusts focused on healthcare and life-sciences credit, along with closed-end funds offering yield from private credit or royalty strategies. The main risks centre on credit and default exposure, portfolio concentration and liquidity constraints, regulatory and tax changes affecting royalty arrangements and cross-border lending, and volatility in market conditions, interest rates, and the trust's own discount to net asset value.
- Credit and default risk in underlying portfolio assets. When a borrower becomes insolvent or a product fails, loan and royalty cash flows can contract materially.
- Concentration and liquidity risk stemming from a relatively small number of large life-science credits and illiquid royalty positions
- Regulatory, Patent, Reimbursement, and Tax Changes Affecting Pharmaceutical Product Sales and Cross-Border Royalty Enforcement
- Market risk for listed trusts encompasses three primary mechanisms: interest-rate movements, shifts in the closed-end fund discount or premium to net asset value, and fluctuations in investor appetite for private credit and royalty strategies.
Competitive landscape
BioPharma Credit PLC (BPCR.LSE) is a UK-listed specialist lender that deploys capital into debt instruments secured by royalties and cash flows from approved life-science products. It operates within a competitive landscape that includes other listed alternative credit vehicles focused on life sciences, dedicated biotech financing platforms, and broader asset managers providing capital to the sector. The investment thesis carries several material risks. Concentration risk emerges from exposure to a limited borrower base, creating dependency on a handful of positions. Credit risk follows naturally from this structure—if a key obligor encounters trouble, the portfolio absorbs the impact disproportionately. Market and NAV volatility tracks closely to underlying drug sales trajectories and regulatory approvals, meaning the fund's quoted value can swing meaningfully on clinical or commercial developments outside traditional market movements. The illiquid nature of private debt assets introduces refinancing risk; if debt needs rolling or the fund faces redemption pressure, exit options may be constrained. Regulatory or tax changes affecting how royalty structures are treated, or shifts in investment trust classification rules, could alter the economics materially.
| Company | Ticker |
|---|---|
| HarbourVest Global Private Equity (as comparator fund manager exposures) | HVPE.LSE |
| 3i Infrastructure | 3IN.LSE |
| Man Group | EMG.LSE |
| Abrdn (abrdn plc) | ABDN.LSE |
| Alliance Trust | ATST.LSE |
Private competitors
- Specialist royalty financiers and private life‑science credit managers (e.g., healthcare royalty buyers and dedicated biotech debt funds)
Get More Stock Analyses Like This
Receive hand-picked stock recommendations with detailed analyses every week
Start Free TrialCatalysts
- Upcoming dividend payment on 27. February 2026 (ex-day 2. February)
- Further growth in the life science lending business through new financing rounds
- Possible portfolio expansion with increasing demand for biotech financing
- Stabilization of the share price after reaching the 52-week low
Analysis
Performance Figures of BioPharma Credit PLC
Relative Performance vs Benchmarks
| Period | BioPharma Credit PLC | vs DAX | vs S&P 500 (SPY) |
|---|---|---|---|
| 1M | +2.09% | +5.42% | +0.68% |
| 3M | +2.52% | +2.43% | -1.38% |
| 6M | +7.99% | +2.37% | -7.25% |
| 1Y | +15.60% | +12.50% | -2.09% |
| 3Y | +60.59% | -4.49% | -27.49% |
| 5Y | +73.99% | +8.65% | -16.25% |
Get More Stock Analyses Like This
Receive hand-picked stock recommendations with detailed analyses every week
Start Free TrialHistorical valuation trends
How the company’s key valuation ratios (P/E, P/S, P/B and P/CF) have evolved over time compared to today.
| Period | P/E Ratio | P/S Ratio | P/B Ratio | P/CF Ratio |
|---|---|---|---|---|
| Current | 8.5 | 7.9 | 1.0 | 8.8 |
| 1Y ago | 8.6 | 8.6 | 1.0 | 10.8 |
| 3Y ago | 4.7 | 3.9 | 0.8 | 12.1 |
| 5Y ago | 10.6 | 9.7 | 1.0 | 12.8 |
Frequently Asked Questions
Is BioPharma Credit PLC a good investment?
What does BioPharma Credit PLC do?
What are the key metrics for BPCR.LSE?
How has BioPharma Credit PLC's stock price performed?
How is BPCR.LSE valued?
What are the growth catalysts for BioPharma Credit PLC?
- Upcoming dividend payment on 27. February 2026 (ex-day 2. February)
- Further growth in the life science lending business through new financing rounds
- Possible portfolio expansion with increasing demand for biotech financing
- Stabilization of the share price after reaching the 52-week low
What are the key risks when investing in BPCR.LSE?
- Credit and default risk in underlying portfolio assets. When a borrower becomes insolvent or a product fails, loan and royalty cash flows can contract materially.
- Concentration and liquidity risk stemming from a relatively small number of large life-science credits and illiquid royalty positions
- Regulatory, Patent, Reimbursement, and Tax Changes Affecting Pharmaceutical Product Sales and Cross-Border Royalty Enforcement
- Market risk for listed trusts encompasses three primary mechanisms: interest-rate movements, shifts in the closed-end fund discount or premium to net asset value, and fluctuations in investor appetite for private credit and royalty strategies.
Who are the main competitors of BioPharma Credit PLC?
- HarbourVest Global Private Equity (as comparator fund manager exposures) (HVPE.LSE)
- 3i Infrastructure (3IN.LSE)
- Man Group (EMG.LSE)
- Abrdn (abrdn plc) (ABDN.LSE)
- Alliance Trust (ATST.LSE)
Key Metrics
Valuation Metrics
Profitability Metrics
Growth Metrics
Dividend history
Long-term record of paid dividends (amount per share and dividend yield at the time of payment).
| Year | Dividend | Yield at payment | Avg. yield |
|---|---|---|---|
| 2026 | 0.02 USD | – | 2.67% |
| 2026 | 0.02 USD | 1.82% | |
| 2026 | 0.02 USD | 1.87% | |
| 2026 | 0.03 USD | 3.29% | |
| 2025 | 0.03 USD | 3.56% | |
| 2025 | 0.02 USD | 1.94% | |
| 2025 | 0.02 USD | 1.98% | |
| 2025 | 0.03 USD | 3.39% | |
| 2024 | 0.04 USD | 4.17% | |
| 2024 | 0.02 USD | 2.01% | |
| 2024 | 0.02 USD | 1.95% | |
| 2024 | 0.03 USD | 3.18% | |
| 2023 | 0.04 USD | 4.34% | |
| 2023 | 0.02 USD | 2.03% | |
| 2023 | 0.02 USD | 1.82% |
Earnings history & estimates
Historical earnings performance shows how consistently the company meets or exceeds analyst expectations. Forward estimates provide insight into expected profitability and growth trajectory.
Analyst estimates for upcoming periods
Key financial figures
Selected income statement, balance sheet and cash flow figures. Annual and quarterly, based on reported IFRS/GAAP financials.
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | 140.23M | 124.46M | 159.68M | 184.25M | 87.97M |
| Operating income (EBIT) | 129.85M | 122.18M | 108.45M | 182.31M | 84.96M |
| Net income | 129.89M | 122.18M | 108.45M | 182.31M | 84.96M |
| Free cash flow | 91.09M | 111.91M | 123.18M | 184.28M | 96.44M |
| Total assets | 1.17B | 1.20B | 1.36B | 1.36B | 1.37B |
| Equity | 1.15B | 1.18B | 1.34B | 1.34B | 1.36B |
| Net debt | -12.59M | -5.62M | -86.20M | -120.53M | -94.71M |
PWP Leeway UG (haftungsbeschränkt)
